

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 1/26/21

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage	
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Infringuinal revascularized PAD (2) Pediatric VTE (2) COVID-19 MI (PREVENT-HD)	Filed 10/20 Phase III Phase III		
	Aprocitentan	Difficult to treat hypertension (2)	Phase III	Phase III	
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis Crohn's Disease Pediatric Psoriasis	Approved 7/20 Phase IIB/III Phase III	Approved 11/20 Phase IIB/III Phase III	
	SIMPONI® Nipocalimab	UC Monotherapy Pediatric Ulcerative Colitis Warm Autoimmune Hemolytic Anemia	Phase IIB/III Phase III Phase III	Phase IIB/III Phase III Phase III	
Infectious Diseases and Vaccines	CABENUVA®/REKAMBY® (Rilpivirine Long Acting)	HIV Infection	Approved 1/21	Approved 12/20	
	VAC52150	Monovalent Ebola Virus Vaccine	Phase III	Approved 7/20	
	VAC89220	HIV Px Vaccine	Phase III	Phase III	
	VAC31518	Janssen COVID-19 Vaccine	Phase III	Phase III	
Neuroscience	SPRAVATO® (esketamine)	Major Depressive Disorder with Acute Suicidal Ideation or Behavior	Approved 7/20	Filed 1/20	
	ponesimod	Monotherapy for multiple sclerosis	Filed 3/20	Filed 3/20	
	paliperidone palmitate 6 month long-acting injectable	Treatment of Schizophrenia	Filed 10/20	Filed 11/20	
	setorexant	Adjunctive treatment for major depressive disorder with insomnia symptoms	Phase III	Phase III	
Oncology	DARZALEX®	Relapsed Refractory MM 1+ prior lines w/PomDex (2) Amyloidosis (AMY 3001) (2) Smoldering multiple myeloma (SMM3001) (2) Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2) Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Filed 11/20 Approved 1/21 Phase III Phase III Phase III	Filed 11/20 Filed 11/20 Phase III Phase III Phase III	
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2) Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2) Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2) Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III Phase III Phase III Phase III	Phase III Phase III Phase III Phase III	
	ERLEADA® (apalutamide)	Localized prostate cancer High risk prostate cancer (PROTEUS)	Phase III Phase III	Phase III Phase III	
	apalutamide/ abiraterone acetate	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III	
	BALVERSA™ (erdafitinib)	Urothelial cancer (2) Tumor Agnostic Non muscle invasive bladder cancer	Approved 4/19 Phase II Phase II	Phase III Phase II Phase II	
	niraparib / abiraterone acetate	L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone M1 Metastatic Castration-Sensitive Prostate Cancer in combination with abiraterone acetate and Prednisone	Phase III Phase III	Phase III Phase III	
	Ciltacabtagene Autoleuce® (BCMA CAR-T)	Relapsed refractory multiple myeloma (2) Relapsed refractory multiple myeloma w/1-3 PL (2)	Phase II Phase III	Phase II Phase III	
	Amivantamab (EGFR/cMET)	Non Small Cell Lung Cancer (2) Frontline Non Small Cell Lung Cancer in combination with chemotherapy	Filed 11/20 Phase III	Filed 1/21 Phase III	
	Amivantamab / Lazertinib	Non Small Cell Lung Cancer (2)	Phase III	Phase III	
	Teclistamab (BCMA/CD3)	Relapsed refractory multiple myeloma (2)	Phase II	Phase II	
	Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension	Phase III Phase III	Phase III Phase III
		macitentan	Chronic thromboembolic pulmonary hypertension 75mg Pulmonary arterial hypertension 75mg	Phase III Phase III	Phase III Phase III
		UPTRAVI®	Pulmonary arterial hypertension IV Chronic thromboembolic pulmonary hypertension	Filed 9/20 Phase III	Phase III Phase III
			Pediatric pulmonary arterial hypertension	Phase III	Phase III
		Macitentan w/tadalafil FDC	Pulmonary arterial hypertension	Phase III	Phase III

This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
 (2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; aprocitentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacycics, LLC, an AbbVie company; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab);



Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
(2019-2023 Key Filings, As Outlined at 2019 Pharm Business Review)
 Selective Highlights as of January 26, 2021

NMEs APPROVED	NMEs IN REGISTRATION	NME PLANNED FILINGS 2021-2023*	
Oncology	Neuroscience	Oncology	Neuroscience
ERLEADA® (apalutamide) (EU) Non-metastatic prostate cancer BALVERSA™ (erdafitinib) (US) Urothelial cancer	Ponesimod Monotherapy for multiple sclerosis	Niraparib Metastatic castration-resistant prostate cancer (mCRPC) Ciltacabtagene Autoleucel (BCMA CAR-T) Multiple Myeloma	Seltorexant Adjunctive treatment for major depressive disorder with insomnia symptoms
	Oncology	BALVERSA™ (erdafitinib) (EU) Urothelial cancer Cusatuzumab Acute myeloid leukemia Teclistamab (BCMA/CD3) Multiple myeloma Talquetamab (GPRC5D/CD3) Multiple myeloma	Infectious Diseases & Vaccines
Neuroscience	Amivantamab (EGFR/cMET) Non Small Cell Lung Cancer		RSV Sr vaccine RSV vaccine Janssen COVID-19 Vaccine COVID-19
SPRAVATO® (Esketamine) Treatment resistant depression			Cardiovascular & Metabolism
Infectious Diseases & Vaccines		Immunology	RPGR AAV Gene Therapy X-linked retinitis pigmentosa Aprocitanan Difficult to treat hypertension
Monovalent Ebola Vaccine (EU) Ebola virus Disease		Nipocalimab Warm Autoimmune Hemolytic Anemia	

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argenx; Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.